Longevity Articles

Glycine-NAC Supplementation Extends Lifespan in Mice

Glycine-NAC Supplementation Extends Lifespan in Mice
  • A new study finds that supplementing mice with GlyNAC – a combination of glycine and N-acetylcysteine (NAC) as precursors of the natural antioxidant glutathione – increases lifespan and improves multiple aspects of aging.

  • Aging mice that received GlyNAC lived 24% longer than those that did not receive GlyNAC. 

  • This study provides a better understanding of how glutathione deficiency, increased oxidative stress, and mitochondrial dysfunction contributes to the aging process — and it may be reversed with GlyNAC supplementation.

This article was posted on EurekAlert.org:

Many people aspire to live longer, healthier lives. A researcher at Baylor College of Medicine, Dr. Rajagopal Sekhar, associate professor of medicine, has been studying aging for the past 20 years to better understand its biological underpinnings and develop nutritional strategies to promote healthy aging. In today’s issue of the journal Nutrients, Sekhar’s team reports the results of a study in mice, which provides proof-of-concept that supplementing GlyNAC – a combination of glycine and N-acetylcysteine as precursors of the natural antioxidant glutathione – can increase lifespan and improve multiple key age-associated defects.

“Just like a car is subject to wear and tear over many years of use, limiting how long it works well, the natural aging process can progressively deteriorate the body and limit lifespan,” said Sekhar, who is the corresponding author of this paper.

For over two decades, Sekhar has studied natural aging in older humans and aged mice. His work contributes to providing a better understanding of how glutathione deficiency, increased oxidative stress, mitochondrial dysfunction and multiple additional hallmark defects of aging contribute to the aging process and how they can be reversed with GlyNAC supplementation.

“Energy is the currency of life and is generated by mitochondria. However, aging is associated with mitochondrial malfunction, and this could affect energy availability. When we discovered that GlyNAC supplementation can correct mitochondrial defects in aging, we asked an important question: Could GlyNAC supplementation from a younger age extend length of life?” said Sekhar. “To answer this question, we worked with healthy, normal laboratory mice.”

The researchers housed the mice under stable environmental conditions. When mice reach an age of 65-weeks, they typically begin to show a drop in glutathione levels and develop mitochondrial dysfunction and oxidative stress. At this age, Sekhar’s team switched the diets of half of the mice to receive GlyNAC, and the other half continued their diet without the supplement. Except for the GlyNAC supplementation, the diets of both groups were the same regarding the content of protein, fat and carbohydrates. Then, the researchers let the mice continue aging undisturbed and recorded how long they lived.

“We were excited to find that the mice that received GlyNAC lived 24% longer than those that did not receive GlyNAC,” Sekhar said. “We next wanted to understand how GlyNAC works.”

For this, the team conducted a second study in aged mice to investigate mitochondrial dysfunction, glutathione levels, oxidative stress and other hallmarks of aging specifically in the animals’ heart, liver and kidneys, and determined the effect of supplementing GlyNAC on these cellular defects. The researchers chose these organs because they conduct vital functions in the body.

In aged mice, the team found that all three organs had glutathione deficiency, oxidative stress, mitochondrial dysfunction, abnormal mitophagy (difficulty in disposing damaged mitochondria), impaired nutrient sensing and genomic damage. GlyNAC supplementation improved and corrected all these defects in the old mice. The researchers propose that it is the improvement of these fundamental biological defects that contributes to the animals’ longer life.

“But mice are not humans. Could this happen in people? There is published evidence from our human studies showing that GlyNAC supplementation improves similar defects in people,” Sekhar said.

For instance, in a pilot human clinical trial in older adults, Sekhar’s group showed that taking GlyNAC for 24-weeks improved many characteristic defects of aging, including glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, body fat and genomic damage. Importantly, the researchers also observed improvement in muscle strength, gait speed, exercise capacity and cognitive function.

Another exploratory human trial by his team investigated premature aging in people and showed that taking GlyNAC improved and corrected multiple similar defects to reverse premature aging and also increased strength, energy levels, cognitive function and quality of life.

Sekhar thinks that the glycine and NAC (from GlyNAC), combined with glutathione (that GlyNAC helps generate), provide the benefits described above and he calls this combination the ‘power of 3.’ A detailed review of GlyNAC can be found here.

“There is growing interest in being able to improve both healthy aging and longer life, but this is not an easy task. We have investigated aging in mice and in human studies for two decades, and our studies show that GlyNAC supplementation successfully and consistently improves many age-related defects,” Sekhar said. “It is exciting that something as simple as GlyNAC can improve several important defects in aging and also extend life.”

Baylor College of Medicine holds an issued patent on the unique combination of Glycine and NAC (GlyNAC) and has licensed it to Nestlé Health Science for use in Celltrient™ Protect and other products. Nestlé Health Science did not provide any funding or support for this research and was not involved with any aspect of this research.

Internal funding from Baylor College of Medicine supported this study.

Premranjan Kumar and Ob W. Osahon are members of Sekhar’s lab called the Translational Metabolism Unit at Baylor College of Medicine and contributed to this work.



Older post Newer post